查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046394

綜合代謝檢測市場－全球產業規模、佔有率、趨勢、機會、預測：分析師、疾病、最終用途、地區和競爭格局，2021-2031年

Comprehensive Metabolic Panel Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Analytes, By Disease, By End Use (Laboratory, PoC, PoC ), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球綜合代謝指標檢測市場預計將從 2025 年的 128.8 億美元大幅成長至 2031 年的 227.2 億美元，複合年成長率達 9.92%。

體外診斷業界的這一細分市場專注於血液檢測，透過分析包括血糖、鈣、電解質和蛋白質在內的14種特定生物標記來評估整體代謝狀態和器官功能。推動這一市場成長的關鍵因素包括糖尿病和腎臟疾病等慢性疾病在全球範圍內的日益流行（這些疾病需要持續監測），以及人口老化帶來的預防性健康篩檢的需求增加。不斷成長的臨床需求正在推動基礎設施的顯著發展，例如，美國病理學家協會在2024年認證了657家新檢查室，這標誌著診斷檢測能力的顯著提升。

市場概覽
預測期 2027-2031
市場規模：2025年 128.8億美元
市場規模：2031年 227.2億美元
複合年成長率：2026-2031年 9.92%
成長最快的細分市場 肝病
最大的市場 北美洲

然而，該市場面臨許多挑戰，主要源自於日益嚴格的監管環境和不斷增加的報銷壓力。特別是，檢查室自建檢測方法的監管力度加大，導致合規要求複雜化、營運成本上升，並為診斷服務供應商帶來了更大的不確定性。這些監管障礙，加上熟練的臨床實驗室技術人員持續短缺，可能導致檢測能力下降和利潤率降低，進而可能阻礙市場擴大營運規模以滿足不斷成長的患者需求。

市場促進因素

全球綜合代謝檢測市場的主要促進因素是慢性代謝性疾病和文明病在全球範圍內的日益普遍。隨著心血管疾病、糖尿病和腎功能障礙等疾病的日益蔓延，臨床上對常規血液生物化學檢驗的需求不斷成長，以監測器官功能和代謝穩定性。這些綜合檢測對於建立健康狀況的基準指標和追蹤疾病進展至關重要，並且逐漸成為標準臨床護理中不可或缺的一部分。例如，根據美國心臟協會於2025年1月發布的《2025年心臟病和中風統計數據更新》，美國約有1.279億成年人將患有某種形式的心血管疾病，這凸顯了需要定期進行代謝評估和持續監測的患者群體極其龐大。

同時，快速成長的老齡人口持續推動著市場規模的成長，因此需要頻繁進行預防性篩檢，以便及早發現與老齡化相關的器官功能障礙。老年患者通常伴隨多種合併症，需要持續監測電解質平衡、腎絲球濾過率和肝臟酵素——這些都是代謝指標分析的基本要素。這一人口趨勢迫使醫療保健系統優先考慮早期診斷干預，以降低長期照護成本。世界衛生組織（世衛組織）2025年2月發布的《老化與健康》概況介紹預測，2030年，全球60歲以上人口將達到14億人。為了應對日益成長的診斷負擔，主要行業參與者正在擴大業務規模。例如，Labcorp在2025年2月發布的2024年第四季及全年業績新聞稿中指出，其全年營收將達到130.1億美元，這表明需要擴大診斷服務的規模才能滿足這一需求。

市場挑戰

全球綜合代謝檢測市場面臨嚴峻挑戰，法規環境日益嚴格，報銷壓力不斷增加。這種嚴峻的情況迫使實驗室在日益緊張的財務狀況下運營，直接阻礙了它們從不斷成長的代謝檢測需求中獲益。隨著政府和私人保險公司實施更嚴格的收費系統和合規要求，診斷服務提供者發現自己缺乏資金投資於必要的基礎設施改善和人員擴充。因此，擴大營運規模以滿足老齡化社會需求的經濟可行性降低，各機構往往被迫優先考慮成本控制而非設備升級。

近期行業數據顯示，當前情況嚴峻，凸顯了這項財務壓力。美國臨床實驗室協會 (ACLA) 報告稱，到 2025 年，《保護醫療保險取得法案》(Protecting Access to Medicare Act) 將迫使臨床實驗室預計約 800 項特定檢測的報銷額度將大幅削減，降幅高達 15%。這些預期的削減造成了不確定性和財政緊縮的局面，進而阻礙了市場成長。由於實驗室被迫承受如此巨大的收入損失，其維持充足檢測能力以進行諸如綜合代謝指標檢測等關鍵診斷工具的能力將受到直接影響。

市場趨勢

全球綜合代謝檢測市場正因全實驗室自動化 (TLA) 系統的普及而發生根本重組，該系統整合了檢測工作流程。實驗室正逐步從使用單一儀器轉向整合式臨床化學平台，以最佳化葡萄糖和電解質等關鍵代謝生物標記的分析。這項技術革新旨在提高檢測能力並減少物理空間需求，從而有效滿足高通量檢測環境下的效率需求。貝克曼庫爾特公司近期發布的 DxC 500i 臨床分析儀等整合硬體獲得監管部門核准，便是這項整合的顯著例證。正如該公司在 2025 年 3 月的新聞稿中所宣布的，該設備結合了化學分析和免疫檢測功能，可提高空間受限檢查室的效率。

同時，旨在提高資料解讀準確性的人工智慧 (AI) 整合正成為一項關鍵趨勢。診斷服務提供者正在部署先進的數位生態系統，利用 AI 來簡化檢體流轉、預測設備維護需求並檢驗代謝數據中的模式。這種數位基礎設施對於管理複雜的檢測結果流程以及確保與更廣泛的醫療保健網路無縫整合至關重要。關鍵產業應用案例表明，這種數位轉型已廣泛發生。例如，羅氏公司在 2025 年 12 月發表的報導《回顧 2025：借助全面整合式解決方案推進診斷》重點介紹了 AI 驅動的數位化解決方案在增強診斷決策和最佳化工作流程方面的快速應用，在其 navify 生態系統中已識別出超過 1500 個數位化應用案例。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球綜合代謝指標檢測市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依項目測量（K+、Na+、Cl-、CO2、葡萄糖、BUN、肌酸酐、Ca++、白蛋白、總蛋白、ALP、ALT、AST、總膽紅素）
    • 疾病特定類別（腎臟病、肝病、糖尿病、其他）
    • 依應用領域（臨床檢查室、即時檢測、即時檢測設備）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美綜合代謝檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲綜合代謝檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區綜合代謝指標檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲綜合代謝檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲綜合代謝指標檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球綜合代謝偵測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott Laboratories
  • Quest Diagnostics Incorporated
  • Laboratory Corporation of America Holdings Limited
  • Sonic Healthcare Limited
  • Unipath Specialty Laboratory Limited
  • SYNLAB International GmbH
  • Genoptix, Inc.
  • Nova Medical, Inc.
  • Mindray Medical International Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 29090

The Global Comprehensive Metabolic Panel Testing Market is expected to expand considerably, from USD 12.88 Billion in 2025 to USD 22.72 Billion by 2031, demonstrating a 9.92% Compound Annual Growth Rate. This market segment within the in vitro diagnostics industry focuses on blood tests that evaluate overall metabolic state and organ function by analyzing fourteen specific biomarkers, including glucose, calcium, electrolytes, and proteins. Key factors fueling this growth include the rising global incidence of chronic conditions like diabetes and kidney disease, which require ongoing monitoring, coupled with an aging population necessitating increased preventive health screenings. This heightened clinical demand has spurred substantial infrastructure development, as evidenced by the College of American Pathologists accrediting 657 new laboratories in 2024, indicating significant expansion in diagnostic testing capabilities.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 12.88 Billion
Market Size 2031USD 22.72 Billion
CAGR 2026-20319.92%
Fastest Growing SegmentLiver Disease
Largest MarketNorth America

However, the market faces considerable challenges, primarily stemming from a more stringent regulatory landscape and increasing pressures on reimbursement. Stricter oversight, particularly for laboratory-developed tests, has imposed intricate compliance requirements, elevating operational expenses and introducing uncertainty for diagnostic service providers. These regulatory obstacles, combined with an ongoing scarcity of skilled clinical laboratory technologists, are likely to impede testing capacity and reduce profit margins, potentially hindering the market's ability to fully expand its operations to meet the increasing patient demand.

Market Driver

A primary catalyst propelling the Global Comprehensive Metabolic Panel Testing Market is the increasing global prevalence of chronic metabolic and lifestyle disorders. With conditions like cardiovascular disease, diabetes, and renal dysfunction becoming more widespread, the clinical need for routine blood chemistry analysis to monitor organ function and metabolic stability grows stronger. These comprehensive panels are crucial for establishing baseline health metrics and tracking disease progression, thus becoming integral to standard clinical care. For instance, the American Heart Association's January 2025 '2025 Heart Disease and Stroke Statistics Update' reported that approximately 127.9 million U.S. adults had some form of cardiovascular disease, highlighting the extensive patient population requiring regular metabolic assessment and ongoing monitoring.

Simultaneously, the rapidly growing geriatric population acts as a consistent driver of market volume, requiring frequent preventive screenings for early detection of age-related organ dysfunction. Older patients frequently experience comorbidities that demand continuous monitoring of electrolyte balance, kidney filtration rates, and liver enzymes-all fundamental aspects of metabolic panel analysis. This demographic trend compels healthcare systems to emphasize early diagnostic intervention to reduce long-term care expenses. The World Health Organization's February 2025 'Ageing and health' fact sheet projects the global population aged 60 and above to reach 1.4 billion by 2030. To address this increasing diagnostic burden, major industry players are expanding their operations; for example, Labcorp's February 2025 '2024 Fourth Quarter and Full Year Results' press release indicated full-year revenues of $13.01 billion, illustrating the expanding scale of diagnostic services needed to meet this demand.

Market Challenge

The Global Comprehensive Metabolic Panel Testing Market faces a substantial challenge due to an increasingly stringent regulatory environment and mounting reimbursement pressures. This difficult landscape forces laboratories to operate with progressively tighter financial margins, directly hampering their capacity to leverage the growing demand for metabolic testing. As governmental and private payers introduce more restrictive fee schedules and compliance mandates, diagnostic providers find themselves with less capital to invest in vital infrastructure improvements or workforce expansion. This consequently undermines the economic viability of scaling operations to serve an aging population, often compelling facilities to prioritize cost control over expanding capacity.

This financial pressure is underscored by recent industry data emphasizing the gravity of the situation. The American Clinical Laboratory Association reported in 2025 that clinical laboratories anticipated significant payment reductions, potentially up to 15% on nearly 800 specific tests, due to the Protecting Access to Medicare Act. These foreseen cuts foster an atmosphere of uncertainty and financial austerity, thereby impeding market growth. When providers must absorb such substantial revenue losses, their ability to sustain adequate testing throughput for essential diagnostic tools, such as comprehensive metabolic panels, is directly compromised.

Market Trends

The Global Comprehensive Metabolic Panel Testing Market is being fundamentally reshaped by the adoption of Total Laboratory Automation (TLA) systems, which consolidate testing workflows. Laboratories are progressively moving away from individual instruments towards integrated clinical chemistry platforms that optimize the analysis of key metabolic biomarkers like glucose and electrolytes. This technological evolution aims to boost testing throughput and reduce physical space requirements, effectively meeting the operational demand for efficiency in high-volume environments. A notable instance of this consolidation is the recent regulatory approval for integrated hardware, such as Beckman Coulter's DxC 500i Clinical Analyzer, which, as announced in their March 2025 press release, combines chemistry and immunoassay functions to improve efficiency in space-limited laboratories.

Simultaneously, the integration of Artificial Intelligence (AI) for improved data interpretation is emerging as a pivotal trend. Diagnostic providers are implementing advanced digital ecosystems that leverage AI to streamline sample routing, anticipate instrument maintenance needs, and validate metabolic data patterns. This digital infrastructure is becoming indispensable for managing the intricate flow of test results and ensuring smooth integration with larger healthcare networks. The extensive nature of this digital shift is evident in key industry adoption figures; for example, Roche's December 2025 '2025 in review: Advancing diagnostics through total integrated solutions' article noted over 1,500 digital placements within its navify ecosystem, highlighting the swift embrace of AI-driven and digital solutions to enhance diagnostic decision-making and workflow optimization.

Key Market Players

  • Abbott Laboratories
  • Quest Diagnostics Incorporated
  • Laboratory Corporation of America Holdings Limited
  • Sonic Healthcare Limited
  • Unipath Specialty Laboratory Limited
  • SYNLAB International GmbH
  • Genoptix, Inc.
  • Nova Medical, Inc.
  • Mindray Medical International Limited

Report Scope

In this report, the Global Comprehensive Metabolic Panel Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Comprehensive Metabolic Panel Testing Market, By Analytes

  • K+
  • Na+
  • Cl-
  • CO2
  • Glucose
  • BUN
  • Creatinine
  • Ca++
  • Albumin
  • Total protein
  • ALP
  • ALT
  • AST
  • Total bilirubin

Comprehensive Metabolic Panel Testing Market, By Disease

  • Kidney Disease
  • Liver Disease
  • Diabetes
  • Others

Comprehensive Metabolic Panel Testing Market, By End Use

  • Laboratory
  • PoC
  • PoC (Instruments)

Comprehensive Metabolic Panel Testing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Comprehensive Metabolic Panel Testing Market.

Available Customizations:

Global Comprehensive Metabolic Panel Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Comprehensive Metabolic Panel Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Analytes (K+, Na+, Cl-, CO2, Glucose, BUN, Creatinine, Ca++, Albumin, Total protein, ALP, ALT, AST, Total bilirubin)
    • 5.2.2. By Disease (Kidney Disease, Liver Disease, Diabetes, Others)
    • 5.2.3. By End Use (Laboratory, PoC, PoC (Instruments))
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Comprehensive Metabolic Panel Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Analytes
    • 6.2.2. By Disease
    • 6.2.3. By End Use
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Comprehensive Metabolic Panel Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Analytes
        • 6.3.1.2.2. By Disease
        • 6.3.1.2.3. By End Use
    • 6.3.2. Canada Comprehensive Metabolic Panel Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Analytes
        • 6.3.2.2.2. By Disease
        • 6.3.2.2.3. By End Use
    • 6.3.3. Mexico Comprehensive Metabolic Panel Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Analytes
        • 6.3.3.2.2. By Disease
        • 6.3.3.2.3. By End Use

7. Europe Comprehensive Metabolic Panel Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Analytes
    • 7.2.2. By Disease
    • 7.2.3. By End Use
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Comprehensive Metabolic Panel Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Analytes
        • 7.3.1.2.2. By Disease
        • 7.3.1.2.3. By End Use
    • 7.3.2. France Comprehensive Metabolic Panel Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Analytes
        • 7.3.2.2.2. By Disease
        • 7.3.2.2.3. By End Use
    • 7.3.3. United Kingdom Comprehensive Metabolic Panel Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Analytes
        • 7.3.3.2.2. By Disease
        • 7.3.3.2.3. By End Use
    • 7.3.4. Italy Comprehensive Metabolic Panel Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Analytes
        • 7.3.4.2.2. By Disease
        • 7.3.4.2.3. By End Use
    • 7.3.5. Spain Comprehensive Metabolic Panel Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Analytes
        • 7.3.5.2.2. By Disease
        • 7.3.5.2.3. By End Use

8. Asia Pacific Comprehensive Metabolic Panel Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Analytes
    • 8.2.2. By Disease
    • 8.2.3. By End Use
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Comprehensive Metabolic Panel Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Analytes
        • 8.3.1.2.2. By Disease
        • 8.3.1.2.3. By End Use
    • 8.3.2. India Comprehensive Metabolic Panel Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Analytes
        • 8.3.2.2.2. By Disease
        • 8.3.2.2.3. By End Use
    • 8.3.3. Japan Comprehensive Metabolic Panel Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Analytes
        • 8.3.3.2.2. By Disease
        • 8.3.3.2.3. By End Use
    • 8.3.4. South Korea Comprehensive Metabolic Panel Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Analytes
        • 8.3.4.2.2. By Disease
        • 8.3.4.2.3. By End Use
    • 8.3.5. Australia Comprehensive Metabolic Panel Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Analytes
        • 8.3.5.2.2. By Disease
        • 8.3.5.2.3. By End Use

9. Middle East & Africa Comprehensive Metabolic Panel Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Analytes
    • 9.2.2. By Disease
    • 9.2.3. By End Use
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Comprehensive Metabolic Panel Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Analytes
        • 9.3.1.2.2. By Disease
        • 9.3.1.2.3. By End Use
    • 9.3.2. UAE Comprehensive Metabolic Panel Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Analytes
        • 9.3.2.2.2. By Disease
        • 9.3.2.2.3. By End Use
    • 9.3.3. South Africa Comprehensive Metabolic Panel Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Analytes
        • 9.3.3.2.2. By Disease
        • 9.3.3.2.3. By End Use

10. South America Comprehensive Metabolic Panel Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Analytes
    • 10.2.2. By Disease
    • 10.2.3. By End Use
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Comprehensive Metabolic Panel Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Analytes
        • 10.3.1.2.2. By Disease
        • 10.3.1.2.3. By End Use
    • 10.3.2. Colombia Comprehensive Metabolic Panel Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Analytes
        • 10.3.2.2.2. By Disease
        • 10.3.2.2.3. By End Use
    • 10.3.3. Argentina Comprehensive Metabolic Panel Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Analytes
        • 10.3.3.2.2. By Disease
        • 10.3.3.2.3. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Comprehensive Metabolic Panel Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Quest Diagnostics Incorporated
  • 15.3. Laboratory Corporation of America Holdings Limited
  • 15.4. Sonic Healthcare Limited
  • 15.5. Unipath Specialty Laboratory Limited
  • 15.6. SYNLAB International GmbH
  • 15.7. Genoptix, Inc.
  • 15.8. Nova Medical, Inc.
  • 15.9. Mindray Medical International Limited

16. Strategic Recommendations

17. About Us & Disclaimer